MedPath

Desvenlafaxine Succinate

These highlights do not include all the information needed to use DESVENLAFAXINE SUCCINATE safely and effectively. See full prescribing information for DESVENLAFAXINE SUCCINATE. Desvenlafaxine Succinate Extended-Release Tablets, for oral use Initial U.S. Approval: 2008

Approved
Approval ID

7195b977-6c91-4fed-837d-9b146f051ce8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 12, 2023

Manufacturers
FDA

Greenstone LLC

DUNS: 825560733

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

desvenlafaxine succinate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59762-1211
Application NumberNDA021992
Product Classification
M
Marketing Category
C73605
G
Generic Name
desvenlafaxine succinate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 1, 2023
FDA Product Classification

INGREDIENTS (10)

DESVENLAFAXINE SUCCINATEActive
Quantity: 50 mg in 1 1
Code: ZB22ENF0XR
Classification: ACTIM
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
HYPROMELLOSE 2208 (15000 MPA.S)Inactive
Code: Z78RG6M2N2
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT

desvenlafaxine succinate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59762-1210
Application NumberNDA021992
Product Classification
M
Marketing Category
C73605
G
Generic Name
desvenlafaxine succinate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 1, 2023
FDA Product Classification

INGREDIENTS (10)

DESVENLAFAXINE SUCCINATEActive
Quantity: 25 mg in 1 1
Code: ZB22ENF0XR
Classification: ACTIM
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
HYPROMELLOSE 2208 (15000 MPA.S)Inactive
Code: Z78RG6M2N2
Classification: IACT

desvenlafaxine succinate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59762-1222
Application NumberNDA021992
Product Classification
M
Marketing Category
C73605
G
Generic Name
desvenlafaxine succinate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 1, 2023
FDA Product Classification

INGREDIENTS (10)

DESVENLAFAXINE SUCCINATEActive
Quantity: 100 mg in 1 1
Code: ZB22ENF0XR
Classification: ACTIM
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT
FD&C YELLOW NO. 6Inactive
Code: H77VEI93A8
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
HYPROMELLOSE 2208 (15000 MPA.S)Inactive
Code: Z78RG6M2N2
Classification: IACT

Drug Labeling Information

DRUG INTERACTIONS SECTION

LOINC: 34073-7Updated: 8/1/2023

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Interactions with Desvenlafaxine

Table 7: Clinically Important Drug Interactions with Desvenlafaxine

Monoamine Oxidase Inhibitors (MAOI)

Clinical Impact

The concomitant use of SSRIs and SNRIs including desvenlafaxine with MAOIs increases the risk of serotonin syndrome.

Intervention

Concomitant use of desvenlafaxine is contraindicated:

With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with desvenlafaxine. 

Within 14 days of stopping an MAOI intended to treat psychiatric disorders. 

In a patient who is being treated with linezolid or intravenous methylene blue. 

[see Dosage and Administration (2.7), Contraindications (4) and Warnings and Precautions (5.2)].

Examples

selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue

Other Serotonergic Drugs

Clinical Impact

Concomitant use of desvenlafaxine with other serotonergic drugs increases the risk of serotonin syndrome.

Intervention

Monitor for symptoms of serotonin syndrome when desvenlafaxine is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of desvenlafaxine and/or concomitant serotonergic drugs [see Warnings and Precautions (5.2)].

Examples

other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort

Drugs that Interfere with Hemostasis

Clinical Impact

Concomitant use of desvenlafaxine with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of desvenlafaxine on the release of serotonin by platelets.

Intervention

Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when Desvenlafaxine is initiated or discontinued [see Warnings and Precautions (5.4)].

Examples

NSAIDs, aspirin, and warfarin

Drugs that are Primarily Metabolized by CYP2D6

Clinical Impact

Concomitant use of desvenlafaxine increases Cmax and AUC of a drug primarily metabolized by CYP2D6 which may increase the risk of toxicity of the CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].

Intervention

Original dose should be taken when co-administered with desvenlafaxine 100 mg or lower. Reduce the dose of these drugs by up to one-half if co-administered with 400 mg of desvenlafaxine.

Examples

desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine

7.2 Drugs Having No Clinically Important Interactions with Desvenlafaxine

Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with desvenlafaxine [see Clinical Pharmacology (12.3)].

7.3 Alcohol

A clinical study has shown that desvenlafaxine does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking desvenlafaxine.

7.4 Drug-Laboratory Test Interactions

False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 8/1/2023

Logo

LAB-0780-8.0

SPL MEDGUIDE SECTION

LOINC: 42231-1Updated: 8/1/2023

MEDICATION GUIDE
Desvenlafaxine Succinate
Extended-Release Tablets

What is the most important information I should know about desvenlafaxine?

Desvenlafaxine can cause serious side effects, including:

**Increased risk of suicidal thoughts or actions in some children and young adults within the first few months of treatment. Desvenlafaxine is not for use in children.**

Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions.  

How can I watch for and try to prevent suicidal thoughts and actions?

o

Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.

o

Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.

o

Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.
**Call your healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:**

thoughts about suicide or dying 

attempts to commit suicide 

new or worse depression 

new or worse anxiety 

feeling very agitated or restless 

panic attacks 

trouble sleeping (insomnia) 

new or worse irritability 

acting aggressive, being angry, or violent 

acting on dangerous impulses

an extreme increase in activity and talking (mania) 

other unusual changes in behavior or mood 

What is desvenlafaxine?

Desvenlafaxine is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder (MDD). Desvenlafaxine belongs to a class of medicines known as serotonin and norepinephrine reuptake inhibitors (SNRIs).

Do not take desvenlafaxine if you:

are allergic to desvenlafaxine, venlafaxine hydrochloride, or any of the ingredients in desvenlafaxine. See the end of this Medication Guide for a complete list of ingredients in desvenlafaxine.

take a monoamine oxidase inhibitor (MAOI).

have stopped taking an MAOI in the last 14 days. Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI.

are being treated with the antibiotic linezolid or the intravenous methylene blue.

Do not start taking an MAOI for at least 7 days after you stop treatment with desvenlafaxine.

Before taking desvenlafaxine tell your healthcare provider about all your medical conditions, including if you:

have high blood pressure

have heart problems

have cerebrovascular problems or had a stroke

have or had bleeding problems

have, or have a family history of, bipolar disorder, mania or hypomania 

have high cholesterol or high triglycerides

have or had depression, suicidal thoughts or behavior

have kidney or liver problems

have or had seizures or convulsions

have low sodium levels in your blood

are pregnant or plan to become pregnant. Talk to your healthcare provider about the risk to your unborn baby if you take desvenlafaxine during pregnancy.

o

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with desvenlafaxine.

o

If you become pregnant during treatment with desvenlafaxine, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-6185.

are breastfeeding or plan to breastfeed. Desvenlafaxine can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with desvenlafaxine.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Desvenlafaxine and other medicines may affect each other causing possible serious side effects. Desvenlafaxine may affect the way other medicines work and other medicines may affect the way desvenlafaxine works.
Especially tell your healthcare provider if you take:

other MAOIs 

medicines to treat migraine headaches known as triptans 

tricyclic antidepressants

fentanyl

lithium

tramadol, fentanyl, meperidine, methadone, or other opioids

tryptophan

buspirone

amphetamines

St. John's Wort 

other medicines containing desvenlafaxine or venlafaxine

medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin

medicines used to treat mood, anxiety, psychotic, or thought disorders, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)

Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take desvenlafaxine with your other medicines.
Do not start or stop any other medicines during treatment with desvenlafaxine without talking to your healthcare provider first. Stopping desvenlafaxine suddenly may cause you to have serious side effects. See, "What are the possible side effects of desvenlafaxine?"
Know the medicines you take. Keep a list of them to show to your healthcare providers when you get a new medicine.

How should I take desvenlafaxine?

Take desvenlafaxine exactly as your healthcare provider tells you to.

Take desvenlafaxine 1 time a day at about the same time each day.

Desvenlafaxine may be taken either with or without food.

Swallow desvenlafaxine tablets whole, with fluid. Do not divide, crush, chew, or dissolve desvenlafaxine tablets.

When you take desvenlafaxine, you may see something in your stool that looks like a tablet. This is the empty shell from the tablet after the medicine has been absorbed by your body.

If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What should I avoid while taking desvenlafaxine?

Do not drive a car or operate heavy machinery until you know how desvenlafaxine affects you.

You should not drink alcohol while taking desvenlafaxine.

What are the possible side effects of desvenlafaxine?

Desvenlafaxine can cause serious side effects, including:

1.

**See, "****What is the most important information I should know about desvenlafaxine?****"**

2.

**Serotonin syndrome.** A potentially life-threatening problem called serotonin syndrome can happen when you take desvenlafaxine with certain other medicines. See, "Do not take desvenlafaxine if you:" Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of serotonin syndrome:

agitation

confusion

fast heart beat

dizziness

flushing

tremors, stiff muscles, or muscle twitching

seizures

seeing or hearing things that are not real (hallucinations)

coma

changes in blood pressure

sweating

high body temperature (hyperthermia)

loss of coordination

nausea, vomiting, diarrhea

**New or worsened high blood pressure (hypertension).** Your healthcare provider should check your blood pressure before and during treatment with desvenlafaxine. If you have high blood pressure, it should be controlled before you start treatment with desvenlafaxine.

**Increased chance of bleeding or bruising.** Taking desvenlafaxine with aspirin, NSAIDs, or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising. 

**Eye problems (angle closure glaucoma).** Many antidepressant medicines, including desvenlafaxine, may cause a certain type of eye problem called angle-closure glaucoma. Call your healthcare provider if you have changes in your vision or eye pain.

**Discontinuation syndrome.** Suddenly stopping desvenlafaxine when you take higher doses may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include the following, some of which can be severe and last for a long time:

dizziness

irritability and agitation

anxiety

aggressiveness (including hostility, rage)

tremor

sweating

seizures

ringing in your ears (tinnitus)

nausea

problems sleeping

tiredness

confusion

electric shock sensation (paresthesia)

headache

diarrhea

abnormal dreams

changes in your mood

hypomania

problems with eyesight (such as blurred vision and trouble focusing)

increase in blood pressure

**Seizures (convulsions).**

**Low sodium levels in your blood (hyponatremia).** Low sodium levels can happen during treatment with desvenlafaxine. Low sodium levels in your blood may be serious and may cause death. Signs and Symptoms of low sodium levels in your blood may include: 

o

headache

o

difficulty concentrating

o

memory changes

o

confusion

o

weakness and unsteadiness on your feet which can lead to falls
**In severe or more sudden cases, signs and symptoms include:**

o

hallucinations (seeing or hearing things that are not real)

o

fainting

o

seizures

o

coma

**Lung problems.** Some people who have taken the medicine venlafaxine which is the same kind of medicine as the medicine in desvenlafaxine have had lung problems. Symptoms of lung problems include difficulty breathing, cough, or chest discomfort. Tell your healthcare provider right away if you have any of these symptoms.

**Sexual Problems (dysfunction).** Taking serotonin and norepinephrine reuptake inhibitors (SNRIs), including desvenlafaxine, may cause sexual problems.  

Symptoms in males may include:

o

Delayed ejaculation or inability to have an ejaculation

o

Decreased sex drive

o

Problems getting or keeping an erection
Symptoms in females may include:

o

Decreased sex drive

o

Delayed orgasm or inability to have an orgasm
Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with desvenlafaxine. There may be treatments your healthcare provider can suggest.

The most common side effects of desvenlafaxine include:

nausea

problems sleeping

constipation

decreased appetite

sexual function problems

dizziness

sweating

feeling sleepy

anxiety

These are not all the possible side effects of desvenlafaxine.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store desvenlafaxine?

Store desvenlafaxine at room temperature between 68°F to 77°F (20°C to 25°C). 

**Keep desvenlafaxine and all medicines out of the reach of children.**

General Information about the safe and effective use of desvenlafaxine
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take desvenlafaxine for a condition for which it was not prescribed. Do not give desvenlafaxine to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about desvenlafaxine that is written for healthcare professionals.

What are the ingredients in desvenlafaxine?
Active ingredient: desvenlafaxine
Inactive ingredients:

**25 mg tablet:** hypromellose, microcrystalline cellulose, talc, magnesium stearate, a film coating which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.

**50 mg tablet:** hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.

**100 mg tablet:** hypromellose, microcrystalline cellulose, talc, magnesium stearate, a film coating which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.

This product's label may have been updated. For current full prescribing information, please visit www.greenstonellc.com.

Logo

LAB-0781-7.0
For more information, go to www.greenstonellc.com or call 1-800-438-1985.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: 8/2023

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.